Intelligent Design of Targeted Radiomers to Unlock First-in-Class Oncology Targets COF-01 & ALT-01

• Expanding radiopharmaceutical reach by drugging first-in-class targets COF-01 and ALT-01
• Optimizing tumor delivery through intelligent ligand design and tunable pharmacokinetics
• Accelerating clinical translation with a data-driven selection and prioritization framework

New Company for 2026

Speakers:

Atul Varadhachary

President

Radiomer Therapeutics